Modernizing and Ensuring PBM Accountability Act

Section-By-Section Summary

Section 1. Short Title; Table of Contents.

This section sets out the name of the bill - the “Modernizing and Ensuring PBM Accountability Act” - and lists the Table of Contents of the Act, including all eight of its sections.


This section would require each contract Medicare enters into with a Part D plan (PDP) sponsor to offer outpatient prescription drug benefits provides that any pharmacy benefit manager (PBM) acting on behalf of a plan sponsor has an agreement with the plan sponsor to meet the requirements of the provisions outlined below. All requirements would apply to MA–PD plans, as well as PDPs.

Delinking PBM Income from Prescription Drug Prices

This provision would prohibit PBMs and their affiliates from deriving income or remuneration for covered Part D drugs based on a manufacturer’s price for the drug. Specifically, PBM remuneration must be in the form of a “bona fide service fee” for services provided and such fees must reflect the fair market value for such services. A bona fide service fee would be required to be a flat dollar amount, rather than based or contingent upon the manufacturer list price or other related drug price benchmarks and factors. Part D plan sponsors could continue to accept rebates, discounts, or price concessions that lower net cost for covered Part D drugs.

Consistency in Terms for Pricing Guarantees & Cost Performance Evaluations

This provision would require PBMs to define and apply drug and drug pricing terms in contracts with Part D plan sponsors in a transparent and consistent manner for purposes of calculating or evaluating PBM performance against pricing guarantees or similar cost performance measurements.

Enhanced PBM Reporting Requirements

This provision would set out new requirements for PBMs to annually report drug price and other information to Part D plan sponsors and to the Secretary of Health and Human Services (HHS). PBMs would be required to include information related to several categories, such as information related to covered Part D drugs, drug dispensing, drug costs and pricing, generic and biosimilar formulary placement, PBM affiliates, financial arrangements with consultants, and potential PBM conflicts of interest. The HHS Secretary would be barred from publicly disclosing information obtained from these reports, except in limited circumstances. The information also could not be disclosed in a way that would identify a specific supply chain stakeholder or prices for specific drugs.
Audits & Enforcement

This provision would permit Part D plan sponsors to audit their PBM for compliance with contract requirements, including under these provisions. The Part D plan sponsor would have the right to select the auditor. The PBM would be required to provide information to the auditor necessary to perform the audit and confirm the accuracy of PBM reporting, including information owned or held by a PBM’s affiliate, in a timely manner.

If a PBM is found to be out of compliance with these provisions, the PBM would be required to: (1) disgorge remuneration that violates the delinking provisions; (2) reimburse the PDP sponsor for any civil monetary penalties imposed as a result of violations of these provisions; and (3) be subject to punitive remedies for breach of contract with the PDP sponsor for failing to comply with these provisions. An annual certification of compliance with the provisions outlined above must also be provided by Part D plan sponsors to the HHS Secretary.

Effective Date

The provisions in Section 2 would take effect starting plan year 2026.

Section 3. Ensuring Fair Assessment of Pharmacy Performance and Quality under Medicare Part D.

This provision would require the HHS Secretary to institute standard Part D measures for assessing network pharmacy performance. Under the provision, PDP plan sponsors may only use pharmacy performance measures that are: (1) established or adopted by the HHS Secretary; and (2) relevant to the pharmacy. The HHS Secretary would be required to establish or adopt standardized pharmacy performance measures that were: (1) evidence-based and reasonable; and (2) focused on pharmacy performance related to patient health outcomes and other areas that pharmacies can impact. Rather than establishing some or all of the required performance measures, the HHS Secretary may adopt measures endorsed by a multi-stakeholder consensus organization (such as the Pharmacy Quality Alliance), that has participation from pharmacies, health plans, PBMs, and CMS. This provision would take effect starting plan year 2025.

Section 4. Promoting Transparency for Pharmacies under Medicare Part D.

This provision would establish a process by which Part D plan sponsors provide their network pharmacies with comprehensive information about pricing prescription drug claims to help increase predictability in pharmacy reimbursement. These provisions would take effect starting plan year 2025.

Section 5. Preventing the Use of Abusive Spread Pricing in Medicaid.

This provision would ban PBM spread pricing in the Medicaid program. Spread pricing occurs when a PBM reimburses a pharmacy at a lower amount than the amount charged to the PBM’s health plan client, with the PBM pocketing the difference. Specifically, this provision requires pass-through pricing for covered outpatient drugs reimbursed under Medicaid, including when...
services are provided under contract with managed care organizations. Payment for PBM services would be limited to the ingredient cost for the drug (i.e.: an amount that approximates pharmacy acquisition costs) and a professional dispensing fee. This amount must be passed through in its entirety from the PBM to the pharmacy. These provisions would take effect 18 months after enactment.

Section 6. Ensuring Accurate Payments to Pharmacies Under Medicaid.

This provision would require participation by retail community pharmacies in the National Average Drug Acquisition Cost (NADAC) survey. The NADAC survey measures pharmacy acquisition costs and is often used in the Medicaid program to help inform reimbursement to pharmacies. This provision would take effect 18 months after enactment.

Section 7. OIG Study and Report on Drug Price Mark-Ups in Medicare Part D.

This provision would require the HHS Office of Inspector General (OIG) to investigate the impact of vertical integration between Part D plans, PBMs, and pharmacies including effects on beneficiary out-of-pocket costs and Medicare spending under the Part D program. The OIG must submit a report with its findings to Congress within a specified timeframe.

Section 8. Medicare Improvement Fund.

This provision would direct the $1.726 billion in savings from the Modernizing and Ensuring PBM Accountability Act to the Medicare Improvement Fund.